Browsing by Author "Stathopoulos, G. P."
Now showing items 1-8 of 8
-
Article
Adjuvant Cytotoxic and Endocrine Therapy in Pre- and Postmenopausal Patients with Breast Cancer and One to Nine Infiltrated Nodes: Five-Year Results of the Hellenic Cooperative Oncology Group Randomized HE 10/92 Study
Fountzilas, George; Stathopoulos, G. P.; Kouvatseas, G.; Polychronis, A.; Klouvas, G. D.; Samantas, E.; Zamboglou, N.; Kyriakou, K.; Adamou, A.; Pectasides, Dimitrios; Economopoulos, T.; Kalofonos, H. P.; Bafaloukos, Dimitrios; Georgoulias, V.; Razi, E. D.; Koukouras, D.; Zombolas, V.; Kosmidis, Paraskevas A.; Skarlos, Dimosthenis V.; Pavlidis, Nicholas (2004)The present randomized phase III trial was designed to detect a 15% benefit in relapse-free survival (RFS) or overall survival (OS) from the incorporation of adjuvant tamoxifen to the combination of CNF [cyclophosphamide, ...
-
Article
Dose-dense adjuvant chemotherapy with epirubicin monotherapy in patients with operable breast cancer and ≥ 10 positive axillary lymph nodes
Fountzilas, George; Nikolaides, C.; Aravantinos, Gerasimos; Skarlos, Dimosthenis V.; Kosmidis, Paraskevas A.; Papakostas, P.; Stathopoulos, G. P.; Kontostolis, E.; Bafaloukos, Dimitrios; Pavlidis, Nicholas (1998)Forty-one patients with operable breast cancer and ≥ 10 positive axillary lymph nodes were treated with 6 cycles of dose-dense adjuvant chemotherapy consisting of epirubicin (100 mg/m2) every 2 weeks with G-CSF support. A ...
-
Article
Dose-dense sequential adjuvant chemotherapy with epirubicin, paclitaxel and CMF in high-risk breast cancer
Fountzilas, George; Papadimitriou, C.; Aravantinos, Gerasimos; Nikolaides, C.; Stathopoulos, G. P.; Bafaloukos, Dimitrios; Kalofonos, H. P.; Economopoulos, T.; Skarlos, Dimosthenis V.; Pavlidis, Nicholas; Dimopoulos, M. A. (2001)Dose-dense sequential chemotherapy appears to be a promising approach in the management of patients with operable breast cancer. We evaluated the tolerability of such a novel chemotherapeutic regimen in high-risk patients. ...
-
Article
Paclitaxel and gemcitabine in advanced non-nasopharyngeal head and neck cancer: A phase II study conducted by the Hellenic Cooperative Oncology Group
Fountzilas, George; Stathopoulos, G. P.; Nikolaides, C.; Kalogera-Fountzila, Anna; Kalofonos, H. P.; Nikolaou, A.; Bacoyiannis, Charalambos; Samantas, E.; Papadimitriou, C.; Kosmidis, Paraskevas A.; Daniilidis, J.; Pavlidis, Nicholas (1999)Background: Paclitaxel as monotherapy or in combination with other drugs has demonstrated significant activity in patients with squamous cell carcinoma of the head and neck region (SCCHN). Preclinical studies have shown ...
-
Article
Paclitaxel and gemcitabine vs. paclitaxel and pegylated liposomal doxorubicin in advanced non-nasopharyngeal head and neck cancer. An efficacy and cost analysis randomized study conducted by the Hellenic Cooperative Oncology Group
Fountzilas, George; Papakostas, P.; Dafni, U.; Makatsoris, T.; Karina, M.; Kalogera-Fountzila, Anna; Maniadakis, N.; Aravantinos, Gerasimos; Syrigos, K.; Bamias, A. T.; Christodoulou, C.; Economopoulos, T.; Kalofonos, H. P.; Nikolaou, A.; Angouridakis, N.; Stathopoulos, G. P.; Bafaloukos, Dimitrios; Pavlidis, Nicholas; Daniilidis, J. (2006)Background: The prognosis of patients with recurrent and/or metastatic head and neck cancer (HNC) is poor. Median survival of these patients following chemotherapy is in the range of 6 to 9 months. In the present randomized ...
-
Article
Paclitaxel by three-hour infusion and carboplatin in advanced carcinoma of nasopharynx and other sites of the head and neck: A phase II study conducted by the Hellenic Cooperative Oncology Group
Fountzilas, George; Skarlos, Dimosthenis V.; Athanasiades, A.; Kalogera-Fountzila, Anna; Samantas, E.; Bacoyiannis, Charalambos; Nicolaou, A.; Dombros, N.; Briassoulis, E. Ch; Dinopoulou, M.; Stathopoulos, G. P.; Pavlidis, Nicholas; Kosmidis, Paraskevas A.; Daniilidis, J. (1997)Background: Paclitaxel has been demonstrated to have significant activity in recurrent or metastatic head and neck cancer (HNC). In addition, the combination of paclitaxel and cisplatin is active in untreated patients with ...
-
Article
Paclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer: Long-term efficacy results: A Hellenic Cooperative Oncology Group (HeCOG) study
Aravantinos, Gerasimos; Fountzilas, George; Kosmidis, Paraskevas A.; Dimopoulos, M. A.; Stathopoulos, G. P.; Pavlidis, Nicholas; Bafaloukos, Dimitrios; Papadimitriou, C.; Karpathios, S.; Georgoulias, V.; Papakostas, P.; Kalofonos, H. P.; Grimani, E.; Skarlos, Dimosthenis V. (2005)Background: We compared the combination plus Carboplatin plus paclitaxel, which is considered the treatment of choice for initial chemotherapy of advanced ovarian cancer (AOC) with a regimen combining alternating carboplatin ...
-
Article
Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: Preliminary results of a Hellenic Cooperative Ontology Group study
Skarlos, Dimosthenis V.; Aravantinos, Gerasimos; Kosmidis, Paraskevas A.; Athanasiades, A.; Stathopoulos, G. P.; Pavlidis, Nicholas; Bafaloukos, Dimitrios; Karpathios, S.; Papakostas, P.; Bamia, C.; Fountzilas, George (1997)Ninety previously untreated patients with advanced epithelial ovarian cancer (International Federation of Gynecology and Obstetrics stages IIC, III, and IV) were randomized, after initial cytoreductive surgery, to receive ...